Found 113 articles
Adagene Inc. announced that its board of directors has authorized a share repurchase program under which, Adagene may repurchase up to US$10 million of its ordinary shares in the form of American depositary shares, subject to the relevant rules under the Securities Exchange Act of 1934, as amended, and the Company’s insider trading policy.
Adagene Announces Publication at ASCO of Interim Monotherapy Dose Escalation Data Showing Compelling Safety Profile of Anti-CTLA-4 SAFEbody® ADG126, with Repeat Dosing Across Dose Levels
Adagene Inc., a company transforming the discovery and development of novel antibody-based therapies, announced the publication of data showing the potential best-in-class safety profile of its anti-CTLA-4 monoclonal antibody, ADG126.
Adagene Inc. announced that members of the company’s management will participate in the following upcoming investor conferences.
Adagen Market Analysis, Development, Opportunities, Future Growth and Business Prospects by Forecast To 2027
The data has been collected through extensive primary and secondary research and is validated by experts in the industry.
Antiviral Drugs Market Analysis 2022-2030- Introduction Of New, Improved, And Innovative Drug Formulations Is A Key Factor Driving Market Revenue Growth
Rising incidence of influenza, respiratory syncytial virus activity, and other viral respiratory infections is a key factor driving market revenue growth.
Air Ambulance Service Market Size 2022-2030- Increasing Technological Advancements In Air Ambulance Services Is A Key Revenue Growth-Driving Factor
Rising incidence of trauma, stroke, and heart attack is expected to increase demand for air medical services, which is one of the key factors driving market revenue growth.
Adagene Presents Data Demonstrating First and Best-in-Class Potential for Differentiated Preclinical Antibody Candidates at American Association for Cancer Research (AACR) Annual Meeting 2022
Adagene Inc., a company transforming the discovery and development of novel antibody-based therapies, announced preclinical data showcasing the potential first and best-in-class profile of new antibody candidates.
Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today reported financial results for the full-year ended December 31, 2021, and provided corporate updates.
Adenosine Deaminase Deficiency Market Trends, Revenue, Key Players, Growth, Share and Forecast Till 2027
The industry analysis report is considered a valuable source of information about the global Adenosine Deaminase Deficiency industry and lays stress on the future market scope, emerging industry trends, industry statistics, and market growth potential during the forecast years.
It was a busy week for clinical trial announcements. Here's a look.
Several biopharma companies celebrate the U.S. Food and Drug Administration’s approval for clinical trials involving therapeutics for cancer treatment.
Adagene Announces FDA Clearance to Proceed with Phase 1b/2 Trial of Anti-CTLA-4 ADG126 SAFEbody® in Combination Therapy With Anti-PD-1 Antibody Pembrolizumab
Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced FDA clearance to proceed with a Phase 1b/2 clinical trial of its anti-CTLA-4 monoclonal antibody (mAb), ADG126, in combination with the anti-PD-1 antibody pembrolizumab.
Biopharma companies are preparing to unveil new data for various oncology programs at the American Association for Cancer Research (AACR) Annual Meeting in New Orleans next month.
Adagene Announces Four Poster Presentations on Robust Preclinical Pipeline of Antibody-Based Therapeutics at Upcoming American Association for Cancer Research (AACR) Annual Meeting
Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced publication of four abstracts featuring preclinical data from its expanding pipeline in advance of the AACR Annual Meeting 2022 in New Orleans, Louisiana from April 8-13, 2022.
Shares of Adagene Inc. are up more than 10% in premarket trading after the company announced a monoclonal and bispecific antibody collaboration with Sanofi valued at up to $2.5 billion.
Adagene Announces SAFEbody® Multi-Target Collaboration with Sanofi for Novel Masked Immuno-Oncology Antibody Candidates
Adagene Inc. announced a collaboration and exclusive license agreement with Sanofi to generate masked monoclonal and bispecific antibodies for development and commercialization by Sanofi.
Adagene Inc. announced that members of the company’s management will participate in one-on-one investor meetings and provide a corporate update at the SVB Leerink 11th Annual Global Healthcare Conference, to be held virtually February 14-18, 2022.
Adagene Inc., a company transforming the discovery and development of antibody-based therapies, announced board and management appointments aimed at supporting the company’s pipeline growth and corporate development.
Adagene Announces First Patient Dosed with Novel, Proprietary Combination of Anti-CD137 Agonist, ADG106, and Anti-CTLA-4 Monoclonal Antibody, ADG116
Adagene Inc. today announced the first patient has been dosed in a combination cohort of its anti-CD137 agonist, ADG106, with its anti-CTLA-4 monoclonal antibody (mAb), ADG116, in patients with advanced/metastatic solid tumors.
Dr. Gandara, Professor and Senior Advisor to the Thoracic Oncology Program at University of California Davis, brings deep expertise and strategic vision in cancer drug and biomarker development.